HERON THERAPEUTICS, INC. /DE/ (HRTX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, HERON THERAPEUTICS, INC. /DE/'s filing signal turned negative.

Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations for acute care and oncology patients. The company's portfolio includes ZYNRELEF for postoperative pain management, APONVIE for postoperative nausea and vomiting, CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting. Heron utilizes its proprietary Biochronomer drug delivery technology to create extended-release formulations. Its U.S.-based sales and marketing team, supported by a co-promotion agreement for ZYNRELEF, targets healthcare professionals in acute care and oncology settings. The company relies on third-party manufacturers for product production.

Revenue is primarily driven by the sales of its four commercial products: ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. Sales are influenced by market acceptance, physician perception, formulary acceptance, and reimbursement from third-party payors.